Stay Informed. Stay Competitive with FREE Insights on the Stock Market, Dow 30 & Emerging Opportunities. Get Free Email Updates

Stay Competitive With Stock Market Updates!

Get Free Updates

Johnson & Johnson Poised To Commence 60K Participant Phase 3 COVID-19 Vaccine Trial In September

By John F. Heerdink, Jr.

As per reports, Johnson & Johnson (JNJ) is set to commence the large scale late-stage trial of its potential coronavirus vaccine next month. The trial is looking forward to enrolling up to 60,000 healthy people randomly selected from the age of 18 years and above across 180 locations in the U.S. and other countries. Participants to receive a dose of the potential vaccine or a placebo, determining the effectiveness and safety of the vaccine, which will further be followed by researchers for more than two years.

J&J’s trial is expected to be the largest coronavirus vaccine testing to date, companies like Moderna and Pfizer conducting late-stage trials for their potential vaccines last month are expected to enroll 30,000 participants. J&J informed that it will use the same technology that was used for its experimental Ebola vaccine, the COVID-19 vaccine is combined using genetic material from the coronavirus with a modified adenovirus (known to cause common colds in humans).

“Our Phase 3 program is intended to be as robust as possible, could include up to 60,000 participants and will be conducted in places with high incidence rates. We are using epidemiology and modeling data to predict and plan where our studies should take place and expect that to be finalized soon.” stated J&J spokesman Jake Sargent to CNBC.

Reportedly, there are more than 160 vaccines under development globally, out of which at least 30 are already in clinical trials, as per the World Health Organization. J&J to produce 600 million to 900 million doses by April if the vaccine is a success.

Dow 30 component Johnson & Johnson (JNJ) is a worldwide healthcare focused company that embraces research and science so that it can provide customers with innovative ideas, products, and services. To learn more about Johnson & Johnson (JNJ) and to continue to track its progress visit the Vista Partners Johnson & Johnson Coverage Page.

Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.

Stay Informed! Stay Competitive! Please join us at Vista Partners and receive our FREE email updates throughout the week and view our exclusive content and research.


Post View Count : 492
(Read Original Story: Johnson & Johnson to start late-stage coronavirus vaccine trial in September with up to 60,000 people in CNBC)


YOUR GUIDE TO STAYING INFORMED IN THE MARKETS

Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Connect with us